MyOr

Company Overview

Snapshot

Founded in April 2018 by Dr. Ariel Katz and Michael Brandwein, MyOr operates with 11–50 employees. The company has raised $5.5M across two funding rounds from five investors. In October 2023, MyOr Diagnostics won the prestigious BNEW Prize for Best New Health Startup.

Business overview

MyOr develops noninvasive monitoring technologies that leverage data-driven artificial intelligence to predict and prevent chronic conditions, specifically focusing on food allergies, eczema, and related conditions in children. The company's AI-driven platform and team of licensed dietitian nutritionists promote evidence-based practices and nutrition strategies. MyOr serves the Health Tech & Life Sciences sector, aiming to improve health outcomes and empower healthcare providers and caregivers with personalized solutions to eliminate preventable conditions.

Strategic signal

MyOr Diagnostics' recognition with the prestigious BNEW Prize for Best New Health Startup in October 2023 signals strong industry validation for its AI-driven platform. This award highlights the company's innovative approach to preventive healthcare for children and its potential to significantly impact the market by mitigating chronic conditions like food allergies and eczema. For investors, this indicates a promising trajectory and reinforces MyOr's position as a leader in the health tech space.

Company Intelligence Q&A

When was MyOr founded and by whom?

MyOr was founded in April 2018 by Dr. Ariel Katz and Michael Brandwein.

What significant award did MyOr receive in 2023?

In October 2023, MyOr Diagnostics won the prestigious BNEW Prize for Best New Health Startup.

Has MyOr begun commercialization in the US?

In October 2020, MyOr began US commercialization of its platform designed to prevent allergic conditions.

What is MyOr's NURTURE platform?

In June 2021, MyOr launched NURTURE Precision Infant Care, an early intervention platform specifically designed for tackling childhood allergies.